Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

Counterfeit anti-cancer drug Avastin raises concerns

The market is flooded with a counterfeit version of cancer drug Avastin worry doctors and patients. Injectable drugs have become increasingly attractive to counterfeiters, in part because they often fetch a higher price than regular pills.

15 Feb 2012

Debate shifts on contraception rule

While congressional Republicans say the fight isn't over on the administration's birth control mandate, the measured support for President Obama's compromise from some Catholic groups and a few Republicans has tamped down the political furor.

15 Feb 2012

NTRR completes research and development of new erectile dysfunction treatment

With Neutra Corp.'s Pure Plus weight-loss supplement already in the midst of clinical trials, the company announced today that it has completed research and development of its next product in the Pure Plus line: an all-natural erectile dysfunction (ED) treatment.

13 Feb 2012

ED can lead to potential cardiovascular disease in men

More than 12 million men have type 2 diabetes and that number is growing at an alarming rate. A little talked about complication of this disease is erectile dysfunction (ED), which can lead to an even more serious condition.

7 Feb 2012

Sex declared safe for heart patients

A doctors’ group on Thursday suggested that sex may be safe for most heart patients. The American Heart Association added that having sex only slightly raises the chance for a heart attack. And that’s true for people with and without heart disease. Despite the higher risk for a heart patient to have a second attack, there’s no evidence that they have more sex-related heart attacks than people without cardiac disease. The updated advice was released online Thursday in the heart association journal, Circulation.

22 Jan 2012

Ampio announces two new European patents for Zertane combination therapy

Ampio Pharmaceuticals, Inc., today announced notification by the European Patent Office they will be awarded two new patents in Europe for the combination of Zertane with any erectile dysfunction drug of the PDE5 inhibitors family such as sildenafil, tadalafil and the likes and for a combination of Zertane with compounds that reduce the side effects of tramadol.

18 Jan 2012

FDA EMDAC schedules to review VIVUS' Qnexa NDA for treatment of obesity

VIVUS, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review the Company's New Drug Application (NDA) for Qnexa for the treatment of obesity on February 22, 2012.

26 Dec 2011

AtheroNova establishes clear development plan for AHRO-001 after positive FDA feedback

AtheroNova Inc., a biotech company focused on the research and development of compounds to regress atherosclerotic plaque has established a clear development plan, including Phase I and Phase II protocol outlines, based on the recently finalized minutes of its pre-IND meeting with the U.S. Food and Drug Administration (FDA) for its AHRO-001, a compound for the treatment of atherosclerosis.

15 Dec 2011

VIVUS announces results of Qnexa clinical study on cardiometabolic disease

VIVUS, Inc. today announced that results from the SEQUEL study were published in The American Journal of Clinical Nutrition, a peer-reviewed journal with broad, multidisciplinary readership.

9 Dec 2011

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that based on the recommendation from the Data Monitoring Committee (DMC) it will discontinue its pivotal double-blinded Phase III MAINSAIL trial that was designed to evaluate the efficacy and safety of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prostate cancer.

23 Nov 2011

Clear link between erectile dysfunction and peripheral neuropathy

Spanish researchers have uncovered clear links between erectile dysfunction (ED) and peripheral neuropathy, according to a paper in the December issue of the urology journal BJUI.

15 Nov 2011

Multiple medication use may increase severity of erectile dysfunction

The use of multiple medications is associated with increased severity of erectile dysfunction, according to a Kaiser Permanente study published online in the British Journal of Urology International.

15 Nov 2011

Fears about ICD shock during sex leads to performance problems in heart patients

Adults with congenital heart disease and implanted cardioverter defibrillators (ICDs) often have a high level of fear and anxiety about the device delivering a shock during sex - resulting in sexual performance problems, according to research (Abstract 14165) presented at the American Heart Association's Scientific Sessions 2011.

14 Nov 2011

Medtronic highlights scientific sessions of interest on program for TCT 2011

Offering the broadest range of medical technology for the interventional and surgical treatment of cardiovascular disease, Medtronic, Inc. today highlighted scientific sessions of interest on the program for TCT 2011, which takes place Nov. 7-11 in San Francisco.

From Medtronic 5 Nov 2011

FDA accepts VIVUS' Qnexa NDA for filing and review

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for Qnexa to treat obesity. The company resubmitted the NDA on October 17, 2011.

4 Nov 2011

Watson receives FDA approval for Androderm lower-dose formulations

Watson Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved its Androderm (testosterone transdermal system) 2 mg and 4 mg formulation.

21 Oct 2011

VIVUS announces Qnexa NDA resubmission for treatment of obesity

VIVUS, Inc. today announced that the company has resubmitted the New Drug Application (NDA) for Qnexa to the U.S. Food and Drug Administration.

18 Oct 2011

Restless legs syndrome linked to hypertension

Up to 15 percent of the population has restless legs syndrome. Restless legs syndrome is characterized by crawling sensations and repeated muscle twichings in one or both legs, and an uncontrollable urge to move them - which may compel a person to walk in circles for hours at night.

12 Oct 2011

NovaSom enters unique agreement with HealthAmerica to treat sleep disorders

NovaSom, Inc., the market leader in technology-driven, payer-aligned cost-saving solutions for obstructive sleep apnea (OSA) management, today announced it has entered a preferred relationship to aid HealthAmerica with managing its sleep disorder diagnostic expenses.

11 Oct 2011

FDA, other regulatory and international partners complete International Internet Week of Action

The U.S. Food and Drug Administration and other regulatory and international partners have completed the International Internet Week of Action (IIWA), a cooperative effort to curb online sales and distribution of counterfeit and illegal medical products.

30 Sep 2011